Q-omics provides the consensus-scored GUCA2B profile across patient tissues and cancer cell-line models. GUCA2B expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, GUCA2B is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, GUCA2B RNA expression shows 8,174 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KICH, KIRC, and ESCA as cancer lineages where GUCA2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GUCA2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GUCA2B survival associations across molecular data types. GUCA2B RNA expression shows survival associations in the most cancer types (20), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GUCA2B RNA expression–survival associations across cancer types. High GUCA2B expression shows unfavorable associations in KICH, LUAD, SCLC, LAML and ESCA, but favorable associations in KIRC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for GUCA2B RNA expression.
This table summarizes GUCA2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for GUCA2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GUCA2B shows lower tumor expression in COAD, READ, LUAD, LUSC and KICH and higher tumor expression in KIRC. The KIRC box plot shows higher GUCA2B RNA expression in tumor versus normal tissue (log2 FC = +3.053, t-test p < 0.001).
This table shows molecular features associated with GUCA2B in patient tissues and cancer cell lines. In patient samples, GUCA2B shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, GUCA2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LIVER and LARGE_INTESTINE.
